HOME > REGULATORY

REGULATORY

PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia

February 4, 2014
Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices

February 3, 2014
PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”

January 31, 2014
Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo

January 30, 2014
Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March

January 30, 2014
2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February

January 30, 2014
3 Entities Strike Codevelopment Deal for Adult TB Vaccines

January 29, 2014
Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA

January 29, 2014
PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3

January 28, 2014
MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation

January 28, 2014
PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin

January 27, 2014
FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA

January 27, 2014
Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study

January 27, 2014
Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn

January 27, 2014
Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines

January 27, 2014
Regulatory Reform Council Eyes New Special System for Mixed Healthcare

January 24, 2014
NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned

January 24, 2014
DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision

January 23, 2014
Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision

January 23, 2014
Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015

January 23, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…